Anteris Technologies Global Corp. — Capital/Financing Update 2011

Jun 28, 2011

29 June 2011

ASX ANNOUNCEMENT

bioMD Announces Name Change to Allied Healthcare Group

• Allied Healthcare Group to trade under ASX Code: AHZ

• Focus on speeding commercialisation of Group’s assets

PERTH, Australia, 29 June 2011: bioMD Limited (ASX: BOD) today announced a change of corporate name to reflect the merger with Allied Medical Ltd earlier this month. The new Company will be called Allied Healthcare Group Ltd and trade under the ASX code AHZ.

Allied Healthcare Group is a diversified healthcare company with assets throughout the medical spectrum, from early stage R&D to product commercialisation and an established medical devices distribution business. Supported by the profitable medical distribution business, the Group includes regenerative tissue engineering technologies with its lead product (CardioCel) having completed a successful Phase II clinical trial and Professor Ian Frazer’s next generation DNA vaccine development company Coridon Pty Ltd.

Lee Rodne, MD of Allied Healthcare Group said: “While benefiting from bioMD’s advanced assets, the new group offers shareholders a much more diversified investment proposition.”

“We have a number of exciting assets in the new group that we will be focusing on for rapid commercialisation. Professor Frazer, best known for developing the Gardasil cervical cancer vaccine, is currently looking at next generation vaccines for a range of infectious diseases and cancers. These new DNA vaccines are particularly exciting as they differ from traditional vaccines, offering both preventative and therapeutic value.”

Allied Healthcare has a majority stake in Coridon, the company established to commercialise Ian Frazer’s vaccine work. Coridon has a unique patented DNA optimisation technology that can potentially be applied to the development of a wide range of vaccines targeting major global diseases.

The Company’s most clinically advanced product is CardioCel, a regenerative patch used to repair paediatric heart deformities. This product has completed a successful Phase II human trial and is based on patented technology known as the ADAPT Tissue Engineering Process (TEP), a method of processing animal derived tissues to produce implantable products that are compatible with the human body.

Allied Healthcare’s distribution business has recorded strong growth over the past five years. The continued expansion of its product offering provides the Group with a strong platform for growth. Growth of the sales and distribution business has been maintained through the establishment of strategic alliances with leading medical equipment manufacturers globally.

ABN 35 088 221 078 PO Box 6879 East Perth Western Australia 6892 T +61 (0) 8 9385 5038 F +61 (0) 8 9385 5028 E info@alliedhealthcaregroup.com.au www.alliedhealthcaregroup.com.au

“As well as the attractive product pipeline and cash flow from our distribution business, we are very fortunate to have a number of exceptional people on our Board and on the share register. These people are key assets to our group as we drive to bring returns to investors through commercial deals, product development and continued sales growth in the distribution business,” Mr Rodne said.

Allied Healthcare Group is 70% owned by the former shareholders of Allied Medical. Significant investors include Andrew Forrest, Avexa and The Clough Family.

For further information please contact:

Lee Rodne, Managing Director +61 8 9266 0190

Michael Bennett, Executive Director +61 8 9385 5038

Media: Paul Dekkers Buchan Consulting +61 2 9237 2800 pdekkers@bcg.com.au

About bioMD Limited

bioMD (ASX: BOD) is an Australian company commercialising innovative tissue engineering technology for use in cardiovascular and soft tissue repair surgery. The ADAPT® technology offers significant improvements to current tissue processing technologies in terms of immunogenicity and tissue durability. Its lead product, CardioCel, has been evaluated in a Phase II human trial in South Africa for various cardiac repair procedures. bioMD is currently maximising shareholder value via pursuit of corporate partnerships, successful completion of clinical milestones and rapid commercialisation strategies.

About Allied Medical Limited

Allied Medical is an Australian based company that is emerging as a major healthcare commercialisation player focused on growing its profitable distribution business providing medical devices and technology to healthcare professionals and building its major interest in Coridon Pty Ltd, developing DNA vaccines for global markets. Allied Medical’s established distribution business consists of innovative and cost effective medical devices and technologies with applications across a broad scope of medical specialties including anaesthesiology, critical care, pain management, infectious diseases, emergency medicine and cardiology. Allied Medical is a major investor in Brisbane based Coridon Pty Ltd, led by Professor Ian Frazer developing next generation DNA vaccines.